Heron Therapeutics, Inc. has entered into a securities purchase agreement to sell 20,734,917 shares of common stock at $1.37 per share and pre-funded warrants to purchase up to 1,162,891 shares at $1.3699 per warrant, and also announced the resignation of its executive vice president and chief operating officer, and issued a press release announcing a cost reduction and restructuring plan.